Mirxes launches HK$1.08b Hong Kong IPO

The group is selling 46.62 million shares.

Singapore biotech firm Mirxes has launched its initial public offering in Hong Kong, seeking to raise $180m (HK$1.08b.)

The group is selling 46.62 million shares, 41,958,000 of the IPO offer will be available to international investors, whilst 4,662,000 shares are available to public subscription in Hong Kong.

“We estimate that we will receive net proceeds of approximately HK$887.6m after deducting the underwriting fees and expenses payable by us in the Global Offering, at the Offer Price of HK$23.30 per Offer Share,” the group said in its bourse filing to the HKEX.

Follow the link for more news on

MiRXES

The people you want to reach are already in this room.

Every quarter, SBR lands on the desks of the founders, CFOs, and directors running Asia's most consequential companies. Every day, they open our newsletter and read our website. It's a room that took twenty years to build — and it's the one most of our partners are trying to get into.

The good news is that the door is open. We work with companies on thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. The shape of the right partnership depends on what you're trying to do, which is why we'd rather start with a conversation than send a rate card.

If you have something this room should know about, tell us. We'll tell you honestly whether we can help, and how.

No rate cards until we understand the brief. It's a better use of everyone's time.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia